 Leigh Perreault
Concepts (325)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prediabetic State | 23 | 2023 | 228 | 7.340 |
Why?
| | Diabetes Mellitus, Type 2 | 46 | 2023 | 2159 | 5.090 |
Why?
| | Insulin Resistance | 29 | 2023 | 1167 | 3.610 |
Why?
| | Hypoglycemic Agents | 22 | 2022 | 1031 | 3.270 |
Why?
| | Blood Glucose | 30 | 2023 | 1936 | 2.830 |
Why?
| | Obesity | 25 | 2023 | 2715 | 2.810 |
Why?
| | Cardiovascular Diseases | 15 | 2020 | 1795 | 2.290 |
Why?
| | Muscle, Skeletal | 19 | 2023 | 1515 | 2.230 |
Why?
| | Insulin | 19 | 2023 | 2157 | 2.090 |
Why?
| | Diabetes Mellitus | 11 | 2023 | 939 | 1.820 |
Why?
| | Sphingolipids | 6 | 2023 | 59 | 1.800 |
Why?
| | Weight Loss | 12 | 2023 | 652 | 1.760 |
Why?
| | Benzhydryl Compounds | 3 | 2017 | 59 | 1.610 |
Why?
| | Glucose Intolerance | 8 | 2020 | 139 | 1.580 |
Why?
| | Diabetic Angiopathies | 3 | 2017 | 261 | 1.550 |
Why?
| | Triglycerides | 10 | 2022 | 515 | 1.510 |
Why?
| | Overweight | 7 | 2022 | 492 | 1.270 |
Why?
| | Diabetes Complications | 2 | 2019 | 218 | 1.210 |
Why?
| | Diglycerides | 5 | 2020 | 56 | 1.190 |
Why?
| | Glucosides | 2 | 2017 | 39 | 1.190 |
Why?
| | Life Style | 12 | 2020 | 431 | 1.100 |
Why?
| | Primary Health Care | 6 | 2023 | 1541 | 1.010 |
Why?
| | Metformin | 13 | 2023 | 293 | 1.000 |
Why?
| | Glucose Tolerance Test | 15 | 2021 | 361 | 0.920 |
Why?
| | Exercise | 10 | 2017 | 1647 | 0.910 |
Why?
| | Anti-Obesity Agents | 1 | 2023 | 49 | 0.880 |
Why?
| | Goals | 2 | 2021 | 164 | 0.870 |
Why?
| | Health Equity | 1 | 2023 | 54 | 0.850 |
Why?
| | Adult | 50 | 2023 | 31327 | 0.840 |
Why?
| | Humans | 89 | 2023 | 118268 | 0.820 |
Why?
| | Nutrition Therapy | 1 | 2022 | 32 | 0.810 |
Why?
| | Middle Aged | 41 | 2023 | 27514 | 0.800 |
Why?
| | Liver | 4 | 2014 | 1803 | 0.800 |
Why?
| | Glucose Clamp Technique | 9 | 2021 | 194 | 0.770 |
Why?
| | Adipose Tissue | 4 | 2023 | 595 | 0.750 |
Why?
| | Hyperglycemia | 4 | 2014 | 313 | 0.730 |
Why?
| | Primary Care Nursing | 1 | 2019 | 3 | 0.730 |
Why?
| | Male | 55 | 2023 | 57479 | 0.680 |
Why?
| | Female | 60 | 2023 | 61268 | 0.680 |
Why?
| | Microvessels | 1 | 2019 | 73 | 0.660 |
Why?
| | Insulin, Long-Acting | 1 | 2019 | 51 | 0.660 |
Why?
| | Obesity Management | 1 | 2018 | 8 | 0.660 |
Why?
| | Peripheral Vascular Diseases | 1 | 2019 | 98 | 0.660 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 1 | 2019 | 74 | 0.650 |
Why?
| | Infant, Newborn, Diseases | 1 | 2019 | 106 | 0.640 |
Why?
| | Awareness | 1 | 2019 | 92 | 0.640 |
Why?
| | Body Mass Index | 11 | 2023 | 2074 | 0.640 |
Why?
| | Fasting | 4 | 2020 | 256 | 0.620 |
Why?
| | Precision Medicine | 1 | 2021 | 354 | 0.600 |
Why?
| | Risk Factors | 19 | 2023 | 8958 | 0.600 |
Why?
| | Weight Reduction Programs | 2 | 2017 | 93 | 0.600 |
Why?
| | Policy | 1 | 2018 | 134 | 0.590 |
Why?
| | Incretins | 2 | 2021 | 15 | 0.580 |
Why?
| | Risk Management | 1 | 2017 | 90 | 0.570 |
Why?
| | Rest | 2 | 2017 | 104 | 0.560 |
Why?
| | Choristoma | 1 | 2015 | 24 | 0.540 |
Why?
| | Sleep Deprivation | 5 | 2021 | 164 | 0.530 |
Why?
| | Insulin-Secreting Cells | 2 | 2010 | 327 | 0.520 |
Why?
| | Weight Gain | 4 | 2019 | 485 | 0.490 |
Why?
| | Lipid Metabolism | 4 | 2021 | 473 | 0.470 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2022 | 1237 | 0.460 |
Why?
| | Glucose | 4 | 2023 | 940 | 0.440 |
Why?
| | Phenols | 1 | 2013 | 85 | 0.440 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 964 | 0.440 |
Why?
| | Glucagon-Like Peptides | 2 | 2022 | 22 | 0.410 |
Why?
| | Physical Endurance | 5 | 2020 | 231 | 0.400 |
Why?
| | Fenofibrate | 1 | 2011 | 24 | 0.390 |
Why?
| | Aged | 17 | 2023 | 19599 | 0.380 |
Why?
| | Hospitalization | 1 | 2019 | 1778 | 0.380 |
Why?
| | Hypolipidemic Agents | 1 | 2011 | 86 | 0.370 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2010 | 44 | 0.360 |
Why?
| | Palmitates | 1 | 2009 | 18 | 0.360 |
Why?
| | Pyrazines | 1 | 2010 | 72 | 0.360 |
Why?
| | Triazoles | 1 | 2010 | 128 | 0.340 |
Why?
| | Energy Metabolism | 4 | 2021 | 762 | 0.340 |
Why?
| | Athletes | 6 | 2020 | 342 | 0.340 |
Why?
| | Biomarkers | 8 | 2023 | 3568 | 0.340 |
Why?
| | Sleep | 4 | 2021 | 651 | 0.340 |
Why?
| | Cross-Sectional Studies | 7 | 2023 | 4523 | 0.320 |
Why?
| | Ceramides | 3 | 2022 | 96 | 0.310 |
Why?
| | Sodium-Glucose Transporter 2 | 2 | 2017 | 21 | 0.300 |
Why?
| | Risk Reduction Behavior | 3 | 2023 | 198 | 0.300 |
Why?
| | Sex Characteristics | 3 | 2021 | 667 | 0.300 |
Why?
| | Diabetic Nephropathies | 2 | 2020 | 288 | 0.300 |
Why?
| | Absenteeism | 2 | 2018 | 38 | 0.290 |
Why?
| | Markov Chains | 2 | 2018 | 118 | 0.290 |
Why?
| | Sex Factors | 5 | 2018 | 1765 | 0.290 |
Why?
| | Health Services | 2 | 2018 | 109 | 0.270 |
Why?
| | Pilot Projects | 2 | 2021 | 1405 | 0.270 |
Why?
| | Adiponectin | 3 | 2018 | 224 | 0.270 |
Why?
| | Lipids | 3 | 2015 | 591 | 0.260 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4575 | 0.260 |
Why?
| | Remission Induction | 3 | 2019 | 246 | 0.260 |
Why?
| | Circadian Rhythm | 3 | 2019 | 394 | 0.260 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2022 | 587 | 0.250 |
Why?
| | Double-Blind Method | 4 | 2022 | 1683 | 0.250 |
Why?
| | Young Adult | 11 | 2019 | 10731 | 0.250 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2019 | 103 | 0.240 |
Why?
| | Lipogenesis | 2 | 2017 | 66 | 0.240 |
Why?
| | Lipoprotein Lipase | 1 | 2004 | 62 | 0.230 |
Why?
| | Dietary Fats | 3 | 2020 | 323 | 0.230 |
Why?
| | Consensus | 3 | 2020 | 533 | 0.220 |
Why?
| | Healthy Lifestyle | 1 | 2023 | 33 | 0.220 |
Why?
| | Physical Exertion | 1 | 2004 | 221 | 0.220 |
Why?
| | Socioeconomic Factors | 2 | 2018 | 1122 | 0.220 |
Why?
| | Computer Simulation | 2 | 2018 | 913 | 0.220 |
Why?
| | Energy Intake | 4 | 2021 | 445 | 0.220 |
Why?
| | Diet, Reducing | 3 | 2017 | 83 | 0.210 |
Why?
| | Prevalence | 2 | 2019 | 2321 | 0.210 |
Why?
| | Sarcolemma | 2 | 2020 | 29 | 0.210 |
Why?
| | Biopsy | 3 | 2018 | 1078 | 0.210 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1163 | 0.210 |
Why?
| | Endpoint Determination | 2 | 2019 | 69 | 0.200 |
Why?
| | Cluster Analysis | 1 | 2023 | 479 | 0.200 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2023 | 192 | 0.200 |
Why?
| | Nephrology | 1 | 2022 | 50 | 0.200 |
Why?
| | Glucose Transporter Type 4 | 1 | 2021 | 38 | 0.200 |
Why?
| | Cytosol | 2 | 2020 | 214 | 0.200 |
Why?
| | Ambulatory Care Facilities | 1 | 2023 | 216 | 0.190 |
Why?
| | Carnitine | 1 | 2021 | 65 | 0.190 |
Why?
| | Oxidation-Reduction | 3 | 2021 | 935 | 0.180 |
Why?
| | Risk Adjustment | 1 | 2020 | 79 | 0.180 |
Why?
| | Endocrinologists | 1 | 2020 | 12 | 0.180 |
Why?
| | New Zealand | 1 | 2019 | 50 | 0.180 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2019 | 48 | 0.180 |
Why?
| | Cytosine | 1 | 2019 | 46 | 0.180 |
Why?
| | Endoplasmic Reticulum | 2 | 2020 | 240 | 0.180 |
Why?
| | Exercise Test | 3 | 2015 | 552 | 0.170 |
Why?
| | Fatty Liver | 1 | 2021 | 247 | 0.170 |
Why?
| | Liraglutide | 1 | 2019 | 27 | 0.170 |
Why?
| | Adolescent | 8 | 2023 | 18364 | 0.170 |
Why?
| | Fatty Acids, Nonesterified | 2 | 2019 | 162 | 0.170 |
Why?
| | United States | 9 | 2023 | 12496 | 0.170 |
Why?
| | Retinal Diseases | 1 | 2019 | 81 | 0.170 |
Why?
| | Models, Econometric | 1 | 2018 | 34 | 0.160 |
Why?
| | Referral and Consultation | 1 | 2023 | 644 | 0.160 |
Why?
| | Postprandial Period | 1 | 2019 | 96 | 0.160 |
Why?
| | Colorado | 3 | 2023 | 4178 | 0.160 |
Why?
| | Quinolizines | 1 | 1997 | 5 | 0.160 |
Why?
| | Drug Combinations | 1 | 2019 | 291 | 0.160 |
Why?
| | Antiemetics | 1 | 1997 | 34 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2019 | 1937 | 0.150 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 211 | 0.150 |
Why?
| | Nausea | 1 | 1997 | 107 | 0.150 |
Why?
| | Cholesterol, HDL | 2 | 2015 | 198 | 0.150 |
Why?
| | Vomiting | 1 | 1997 | 123 | 0.150 |
Why?
| | Health Resources | 1 | 2018 | 130 | 0.150 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2659 | 0.150 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 251 | 0.150 |
Why?
| | Hysterectomy | 1 | 1997 | 117 | 0.140 |
Why?
| | Odds Ratio | 1 | 2019 | 993 | 0.140 |
Why?
| | Patient Participation | 1 | 2019 | 368 | 0.140 |
Why?
| | Body Weight | 3 | 2015 | 923 | 0.140 |
Why?
| | Treatment Outcome | 6 | 2021 | 9319 | 0.140 |
Why?
| | Patient-Centered Care | 1 | 2021 | 493 | 0.140 |
Why?
| | Phosphatidylethanolamines | 1 | 2016 | 66 | 0.140 |
Why?
| | Delivery of Health Care | 1 | 2023 | 863 | 0.140 |
Why?
| | Exercise Therapy | 2 | 2017 | 355 | 0.140 |
Why?
| | Eating | 2 | 2021 | 366 | 0.140 |
Why?
| | Research Design | 2 | 2019 | 961 | 0.130 |
Why?
| | Blotting, Western | 2 | 2016 | 1186 | 0.130 |
Why?
| | Phosphatidylcholines | 1 | 2016 | 131 | 0.130 |
Why?
| | Cost-Benefit Analysis | 1 | 2018 | 551 | 0.130 |
Why?
| | Indoles | 1 | 1997 | 311 | 0.130 |
Why?
| | Qualitative Research | 1 | 2019 | 952 | 0.130 |
Why?
| | Kidney Diseases | 1 | 2019 | 439 | 0.130 |
Why?
| | Patient Compliance | 1 | 2019 | 532 | 0.130 |
Why?
| | Costs and Cost Analysis | 1 | 2015 | 201 | 0.130 |
Why?
| | Sleep Apnea Syndromes | 1 | 2015 | 80 | 0.120 |
Why?
| | Hypoglycemia | 1 | 2019 | 401 | 0.120 |
Why?
| | Income | 1 | 2015 | 173 | 0.120 |
Why?
| | Somatostatin | 1 | 2014 | 53 | 0.120 |
Why?
| | Health Personnel | 1 | 2019 | 579 | 0.120 |
Why?
| | Logistic Models | 1 | 2019 | 1896 | 0.120 |
Why?
| | Employment | 1 | 2015 | 133 | 0.120 |
Why?
| | Pneumonia | 1 | 2019 | 579 | 0.120 |
Why?
| | Recovery of Function | 2 | 2015 | 603 | 0.120 |
Why?
| | Multicenter Studies as Topic | 1 | 2014 | 252 | 0.110 |
Why?
| | Smoking | 2 | 2012 | 1478 | 0.110 |
Why?
| | Cost of Illness | 1 | 2015 | 255 | 0.110 |
Why?
| | Oxygen Consumption | 4 | 2016 | 585 | 0.110 |
Why?
| | Metabolic Diseases | 1 | 2014 | 103 | 0.110 |
Why?
| | C-Reactive Protein | 1 | 2015 | 364 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2019 | 6541 | 0.110 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2012 | 48 | 0.110 |
Why?
| | Fructose | 1 | 2014 | 198 | 0.110 |
Why?
| | Homeostasis | 1 | 2016 | 589 | 0.110 |
Why?
| | Depressive Disorder, Major | 1 | 2015 | 302 | 0.110 |
Why?
| | Prospective Studies | 3 | 2019 | 6443 | 0.110 |
Why?
| | Mitochondria | 1 | 2018 | 785 | 0.100 |
Why?
| | Models, Theoretical | 1 | 2016 | 554 | 0.100 |
Why?
| | Adult Children | 1 | 2011 | 18 | 0.100 |
Why?
| | Placebos | 2 | 2009 | 202 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1433 | 0.100 |
Why?
| | Adipocytes | 1 | 2012 | 195 | 0.100 |
Why?
| | Diabetes, Gestational | 1 | 2015 | 284 | 0.100 |
Why?
| | Age Factors | 1 | 2018 | 2990 | 0.100 |
Why?
| | Health Behavior | 2 | 2023 | 714 | 0.100 |
Why?
| | Metabolomics | 1 | 2015 | 540 | 0.100 |
Why?
| | Quality of Life | 3 | 2019 | 2355 | 0.090 |
Why?
| | Sitagliptin Phosphate | 1 | 2010 | 30 | 0.090 |
Why?
| | Comorbidity | 1 | 2015 | 1516 | 0.090 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2019 | 1183 | 0.090 |
Why?
| | Family Health | 1 | 2011 | 201 | 0.090 |
Why?
| | Longevity | 1 | 2011 | 150 | 0.090 |
Why?
| | Mitochondria, Muscle | 2 | 2021 | 97 | 0.090 |
Why?
| | C-Peptide | 1 | 2010 | 139 | 0.090 |
Why?
| | Tandem Mass Spectrometry | 1 | 2012 | 418 | 0.090 |
Why?
| | Delphi Technique | 2 | 2019 | 163 | 0.080 |
Why?
| | Menopause | 1 | 2011 | 266 | 0.080 |
Why?
| | Leisure Activities | 1 | 2008 | 27 | 0.080 |
Why?
| | Blood Pressure | 1 | 2014 | 1656 | 0.080 |
Why?
| | Body Composition | 1 | 2011 | 644 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 1857 | 0.070 |
Why?
| | Postoperative Complications | 1 | 1997 | 2230 | 0.070 |
Why?
| | Risk Assessment | 3 | 2015 | 3043 | 0.070 |
Why?
| | Mass Screening | 1 | 2013 | 1048 | 0.070 |
Why?
| | Cohort Studies | 4 | 2021 | 5078 | 0.070 |
Why?
| | Fibrinogen | 2 | 2018 | 150 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2012 | 3358 | 0.070 |
Why?
| | Multivariate Analysis | 1 | 2009 | 1469 | 0.070 |
Why?
| | Aging | 1 | 2015 | 1675 | 0.060 |
Why?
| | Regression Analysis | 2 | 2019 | 984 | 0.060 |
Why?
| | Incidence | 3 | 2019 | 2413 | 0.060 |
Why?
| | Health Expenditures | 1 | 1986 | 174 | 0.060 |
Why?
| | Retrospective Studies | 2 | 2019 | 12932 | 0.060 |
Why?
| | Metabolic Clearance Rate | 1 | 2004 | 111 | 0.060 |
Why?
| | Prognosis | 2 | 2023 | 3425 | 0.060 |
Why?
| | Depression | 1 | 2012 | 1133 | 0.060 |
Why?
| | Gene Expression Profiling | 2 | 2023 | 1590 | 0.060 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 4887 | 0.060 |
Why?
| | Alcohol Drinking | 1 | 2009 | 651 | 0.060 |
Why?
| | Hormones | 1 | 2004 | 135 | 0.060 |
Why?
| | Parents | 1 | 2011 | 1208 | 0.060 |
Why?
| | Menstrual Cycle | 1 | 2003 | 113 | 0.060 |
Why?
| | Wakefulness | 2 | 2015 | 128 | 0.050 |
Why?
| | Eligibility Determination | 1 | 2023 | 55 | 0.050 |
Why?
| | Lactic Acid | 1 | 2003 | 278 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1124 | 0.050 |
Why?
| | Disease Progression | 2 | 2019 | 2477 | 0.050 |
Why?
| | Citric Acid Cycle | 1 | 2021 | 45 | 0.050 |
Why?
| | Subcellular Fractions | 1 | 2021 | 83 | 0.050 |
Why?
| | Injections, Subcutaneous | 1 | 2021 | 139 | 0.050 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2020 | 49 | 0.050 |
Why?
| | Protective Agents | 1 | 2020 | 41 | 0.050 |
Why?
| | Kinetics | 1 | 2004 | 1623 | 0.050 |
Why?
| | Motor Activity | 2 | 2015 | 664 | 0.050 |
Why?
| | Education | 1 | 2020 | 104 | 0.050 |
Why?
| | Proprotein Convertase 9 | 1 | 2020 | 60 | 0.040 |
Why?
| | Stearoyl-CoA Desaturase | 2 | 2010 | 56 | 0.040 |
Why?
| | Pregnancy | 2 | 2015 | 5671 | 0.040 |
Why?
| | Poisson Distribution | 1 | 2019 | 68 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2013 | 1288 | 0.040 |
Why?
| | Stakeholder Participation | 1 | 2019 | 70 | 0.040 |
Why?
| | Time Factors | 3 | 2019 | 6368 | 0.040 |
Why?
| | E-Selectin | 1 | 2018 | 51 | 0.040 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2018 | 31 | 0.040 |
Why?
| | Subcutaneous Fat | 1 | 2019 | 78 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2018 | 124 | 0.040 |
Why?
| | Probability | 1 | 2019 | 302 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 154 | 0.040 |
Why?
| | Intra-Abdominal Fat | 1 | 2019 | 89 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2018 | 167 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2020 | 577 | 0.040 |
Why?
| | Research | 1 | 2020 | 406 | 0.040 |
Why?
| | Leptin | 1 | 2018 | 228 | 0.040 |
Why?
| | Diet | 3 | 2012 | 1143 | 0.040 |
Why?
| | Case-Control Studies | 2 | 2017 | 3156 | 0.040 |
Why?
| | Metabolome | 1 | 2019 | 288 | 0.040 |
Why?
| | Biological Transport | 1 | 2017 | 380 | 0.040 |
Why?
| | Adaptation, Physiological | 2 | 2010 | 501 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 410 | 0.040 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 86 | 0.030 |
Why?
| | Diet, Fat-Restricted | 1 | 2015 | 76 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2020 | 533 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2013 | 2491 | 0.030 |
Why?
| | Melatonin | 1 | 2015 | 104 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2018 | 685 | 0.030 |
Why?
| | Kidney | 1 | 2022 | 1351 | 0.030 |
Why?
| | Calorimetry | 1 | 2013 | 59 | 0.030 |
Why?
| | Fatty Acids | 1 | 2016 | 403 | 0.030 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2012 | 59 | 0.030 |
Why?
| | Glycerol | 1 | 2012 | 87 | 0.030 |
Why?
| | Risk | 1 | 2015 | 849 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1522 | 0.030 |
Why?
| | Sleep Wake Disorders | 1 | 2015 | 238 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2010 | 2657 | 0.030 |
Why?
| | Animals | 1 | 2013 | 33152 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2012 | 190 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 4684 | 0.020 |
Why?
| | Calorimetry, Indirect | 1 | 2010 | 72 | 0.020 |
Why?
| | Genetic Variation | 1 | 2015 | 912 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2010 | 38 | 0.020 |
Why?
| | Polysomnography | 1 | 2010 | 156 | 0.020 |
Why?
| | Nicotine | 1 | 2012 | 275 | 0.020 |
Why?
| | Retinoid X Receptor gamma | 1 | 2009 | 4 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 369 | 0.020 |
Why?
| | PPAR alpha | 1 | 2009 | 55 | 0.020 |
Why?
| | Bicycling | 1 | 2010 | 77 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2435 | 0.020 |
Why?
| | Women's Health | 1 | 2011 | 274 | 0.020 |
Why?
| | Coronary Disease | 1 | 2011 | 355 | 0.020 |
Why?
| | Phospholipids | 1 | 2010 | 207 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1622 | 0.020 |
Why?
| | Reference Values | 1 | 2009 | 770 | 0.020 |
Why?
| | Adiposity | 1 | 2012 | 508 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 980 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2015 | 2262 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2011 | 696 | 0.020 |
Why?
| | Infant Care | 1 | 1986 | 43 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1870 | 0.020 |
Why?
| | Infertility | 1 | 1986 | 45 | 0.020 |
Why?
| | Health Promotion | 1 | 2011 | 685 | 0.020 |
Why?
| | Delivery, Obstetric | 1 | 1986 | 125 | 0.020 |
Why?
| | Maternal Health Services | 1 | 1986 | 83 | 0.020 |
Why?
| | Contraception | 1 | 1986 | 117 | 0.020 |
Why?
| | Abortion, Induced | 1 | 1986 | 73 | 0.020 |
Why?
| | Follicular Phase | 1 | 2003 | 41 | 0.010 |
Why?
| | Anaerobic Threshold | 1 | 2003 | 21 | 0.010 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 2003 | 76 | 0.010 |
Why?
| | Luteal Phase | 1 | 2003 | 44 | 0.010 |
Why?
| | Catecholamines | 1 | 2003 | 100 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2011 | 2057 | 0.010 |
Why?
| | Heart Rate | 1 | 2003 | 729 | 0.010 |
Why?
| | Infant, Newborn | 1 | 1986 | 5230 | 0.010 |
Why?
|
|
Perreault's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|